A Study on the Safety and Efficacy of Topiramate in the Treatment of Patients With Bipolar I Disorder

Condition(s) targeted: Bipolar Disorder

Intervention: Topiramate (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Official(s) and/or principal investigator(s):
Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

The primary purpose of this study is to evaluate the safety and efficacy of topiramate compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder.

Official title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study of the Safety and Efficacy of Topiramate in Patients With Acute Manic or Mixed Episodes of Bipolar I Disorder With an Optional Open-Label Extension

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Change from baseline to Day 21 in the total Young Mania Rating Scale (YMRS) score.

Secondary outcome: Changes from baseline to Day 21 and Week 12 in the scores of CGI, MADRS, BPRS, and GAS. Response to treatment, indicated by no longer meeting DSM-IV criteria for manic/mixed episode. Incidence of adverse events monitored throughout the study.

Detailed description: This is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of topiramate (400 milligrams/day) compared with placebo in the treatment of acute manic or mixed episodes in patients with Biplar I Disorder. In addition, a third group of patients will be treated with lithium (1500milligrams/day) as a comparator drug. The trial consists of 3 phases: a screening period; double-blind treatment for 12 weeks; and an optional open-label period of at least 6 months. Efficacy assessments include the change from baseline to Day 21 in the Young Mania Rating Scale (YMRS) score. Also included as efficacy assessments during the 12 week study are the Clinical Global Impressions (CGI) scale, Global Assessment Scale (GAS), Montgomery-Åsberg Depression Rating Scale (MADRS), Brief Psychiatric Rating Scale (BPRS), and health-related quality of life measures at specified time intervals. Safety assessments include evaluation of adverse events throughout the study, rate of withdrawal from the study due to adverse events, and vital signs (blood pressure and pulse) througout the study, as well as changes in clinical laboratory tests (hematology, chemistry, urinalysis), electrocardiograms (ECGs), and physical examinations at specified times. The study hypothesis is that the change from baseline in the total Young Mania Rating Scale (YMSR) score at Day 21 will be significantly better for the topiramate groups than for the placebo group and that the study drug will be well tolerated by the patients. Topiramate oral capsule will be increased from once daily (50mg) to 3 times daily up to target total daily dose 400mg, maintained through Week 12. Lithium oral capsules will be increased from once daily (300mg) to 3 times daily up to target total daily dose of 1500mg, maintained through Week 12.

Minimum age: 16 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: - Diagnosis of Bipolar I Disorder by criteria of Diagnostic and

Statistical Manual of Mental Diseases, 4th edition (DSM-IV) confirmed by the Structured

Clinical Interview for DSM-IV Axis I Disorders (SCID-I - ) - Currently in a manic or mixed

episode and at least one previous manic or mixed episode - meet minimum severity criteria

(a Young Mania Rating Scale [YMRS] score of >=20 at screening and baseline visits) for the

current acute manic or mixed episode - Females must be postmenopausal, surgically sterile,

or using adequate contraceptive measures, and have a negative pregnancy test

Exclusion Criteria: - DSM-IV diagnosis of alcohol or substance dependence (with the

exception of nicotine or caffeine dependence) - DSM-IV Axis I diagnosis of schizoaffective

disorder or impulse control disorder - Experienced a manic episode while taking an

antidepressant or psychostimulant drug - known hypersensitivity to topiramate or

previously participated in a topiramate study

A Study of the Safety and Efficacy of Topiramate in the Treatment of Patients with Bipolar I Disorder

Ending date: November 2002
Last updated: March 14, 2007